I to kliniske studier omhandlende metastatisk renalcellecarcinom, blev mikroangiopatisk hæmolytisk anæmi (MAHA) rapporteret hos 7 ud af 19 patienter behandlet med bevacizumab (10 mg/ kg hver anden uge) og sunitinibmaleat (50 mg daglig) i kombination.
In two clinical studies of metastatic renal cell carcinoma, microangiopathic haemolytic anaemia (MAHA) was reported in 7 of 19 patients treated with bevacizumab (10 mg/ kg every two weeks) and sunitinib malate (50 mg daily) combination.